Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 31, 2025

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

March 24, 2025

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

March 23, 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

March 17, 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

March 16, 2025

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

March 09, 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

March 05, 2025

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

February 17, 2025

Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.

February 10, 2025

Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.

February 05, 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

January 30, 2025

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

January 23, 2025

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

January 02, 2025

Dr Schram discusses the significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

December 30, 2024

Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.

December 30, 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

December 28, 2024

Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.

December 17, 2024

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

December 12, 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

December 12, 2024

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

December 12, 2024

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.